Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures†
HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high‐performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants† ‡
Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia†
Production of β‐globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients†
Severe iron overload in Blackfan‐Diamond anemia
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSF†
A novel missense mutation causing abnormal LMAN1 in a Japanese patient with combined deficiency of factor V and factor VIII†
Short‐term and long‐term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients
C/β0 thalassemia†
The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia†
MRI findings in aplastic anemia†
Modification of gene expression
Hemoglobin H‐constant spring in North America
Uncertainty and discordance in the staging and prognosis of diffuse large B‐cell lymphoma with isolated bilateral testicular involvement†
Possible graft‐versus‐host disease involving the central nervous system soon after cord blood transplantation†
Treatment with hydroxyurea in a patient compound heterozygote for a high oxygen affinity hemoglobin and β‐thalassemia minor†
Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide†
A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin†
Acute monoblastic leukemia with abnormal granules and disseminated intravascular coagulation
Profound neutropenia resulting from metyrapone‐induced adrenal crisis
Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor†
KIR and HLA‐Cw genotypes of donor‐recipient pairs influence the rate of CMV reactivation following non‐T‐cell deleted unrelated donor hematopoietic cell transplantation†